Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs from President Donald Trump.
The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and manufacturing capabilities.
Sanofi鈥檚 current sites in the US stand to benefit from direct investments as the company looks to enhance the robustness of its medicine supply chain amid an uncertain trade landscape.
There are 83,000 people employed by Sanofi worldwide 鈥� 13,000 of whom are based in the US. While the vaccine maker has not publicly disclosed the exact size of its US manufacturing and R&D footprint, its website lists six major locations across three states.
Sanofi鈥檚 innovation hub, which employs 2,500 people, is based in Cambridge, Massachusetts. Swiftwater, Pennsylvania contains the company鈥檚 vaccine production sites, whilst Framingham, Massachusetts houses a biologics factory. Also in Massachusetts is Sanofi鈥檚 Waltham facility, responsible for developing mRNA technology. Sanofi鈥檚 US headquarters is in Bridgewater, New Jersey.
Alongside levelling up existing sites, Sanofi stated it would expand its US presence via partnerships with other domestic manufacturers.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSanofi鈥檚 CEO Paul Hudson said: 鈥淥ur expected investments in the US will be substantial and will help ensure the production of key medicines in the US.”
Companies are moving quickly to shore up US manufacturing capabilities amid tariffs implemented by Trump that have made importing certain products into the country less attractive. The biopharma industry is also bracing itself for pharmaceutical-specific tariffs, a levy continually threatened by Trump. The President signed an executive order last week that will see foreign drug manufacturing plants receive the same level of scrutiny and surprise inspections as US-based facilities, a bid to boost domestic manufacturing.
Sanofi stated that its investment decisions 鈥渨ill be adjusted as the external environment continues to evolve鈥�. In 2024, $21.6bn of its $45.2bn global sales came from the US market.
Sanofi joins a long list of pharma and life science companies redirecting resources to the US in an effort to make supply chains more robust. In April, Roche unveiled a $50bn investment strategy to upgrade three R&D sites in the US. Thermo Fisher has outlaid $2bn to bolster US manufacturing, whilst Novartis, Johnson & Johnson and Eli Lilly have also made respective investment announcements in 2025. The medtech industry is also following in the same vein 鈥� Siemens Healthineers said yesterday (14 May) it would from Mexico to the US for one of its subsidiaries.
Navigate the shifting tariff landscape with real-time data and market-leading analysis.
Request a free demo for GlobalData鈥檚 Strategic Intelligence .
